This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of the clinical data was based on all available data (in effect treatment completers). The primary health outcomes used were fractures in first post-treatment year (vertebral, hip, Colles or other), as well as the duration of therapy. The authors used the following variables to control for baseline characteristic of the study population to avoid possible bias: patient age and gender; type of health insurance coverage (Fee For Service, Health Maintenance Organisation, point-of-service, Preferred Provider Options); use of health care services (cost) by type of service in the 6 months prior to initiation of the drug therapy episode; diagnostic profile, as determined by the ICD-9 codes recorded on paid claims during the prior 6 months and the month in which treatment was initiated; prior fractures (vertebral, hip, Colles, all others); and prior use of the following classes of prescription drugs, non-steroidal anti-inflammatory drugs, arthritis medications, drugs to treat diabetes, vitamin D therapy, anticoagulation therapy, antidepressants and steroids.
Effectiveness results
The study found that bisphosphonate patients were 6.9% more likely to break therapy, (p<0.05) and used 17.7 fewer days of total drug therapy over 1 year, (p<0.0001) than patients treated initially with a single HRT. Bisphosphonate patients were also four times more likely to change therapies than single HRT patients, (p<0.0001).
In comparison, raloxifene patients were uniformly less compliant and more likely to change therapies than single HRT patients, (p<0.0001). Moreover, older patients were more compliant and more likely to change therapies than patients under 55 years of age, (p<0.0001).
The results for fractures indicated that patients treated with bisphosphonates were twice as likely as single HRT patients to experience a vertebral fracture (odds ratio, OR=2.364, p<0.0001), Colles fracture (OR=2.080, p</=0.01) or other fracture (OR=2.073, p<0.0001) in the first post-treatment year.
The risk of fracture was not found to differ between HRT and raloxifene patients. While compliance with therapy for 1 year was found to reduce the likelihood of all types of fractures (OR<1.00), the estimated impact was only statistically 
Clinical conclusions
Patients who achieved 1 year of uninterrupted drug therapy for osteoporosis achieved better patient outcomes than patients who terminated or interrupted therapy during the first year. Compliance with drug therapies for osteoporosis was poor, leaving patients at risk for fractures.
Modelling
Multivariate statistical models were used to take baseline differences between the populations being compared into consideration. Several different multivariate models were developed. For example, simple dichotomous patient outcome measures, such as whether or not a patient completed a year of uninterrupted therapy, switched drugs, or experienced a fracture, were analysed using logistic regression models. Outcome measures based on the time to these events were analysed using Cox proportional hazards models. Continuous outcome measures, such as health care costs over the first year, were analysed using ordinary least-squares (OLS) regression models. For hospital costs that may have a large number of patients with zero values, the two-step approach was used.
Measure of benefits used in the economic analysis
No summary measure of health benefit was used in the economic analysis. The clinical outcomes were left disaggregated. Hence, in effect, a cost-consequences analysis was performed.
Direct costs
The costs associated with treating osteoporosis patients were investigated using the total cost of treating patients over the first year. The total costs were also broken down into the individual components of cost. Such components were drug costs, ambulatory care (physician services), hospital outpatient care, laboratory tests and hospital services. Three alternative models of health care cost were investigated. The first model for drug use patterns used dichotomous variables indicating whether or not the patient achieved 360 days of continuous therapy or switched therapies during the first treatment year. The second model for drug use patterns used the count of days of therapy as its measure of compliance. The third cost model used independent variables for the initial therapy used by the patient with single HRT patients as the comparison group. Simple OLS models were used for all costs, except hospital costs for which a two-part model was estimated. These estimations were based on actual data. Discounting was not carried out, but it was not relevant as the follow-up period was 1 year. The price year was not reported.
Statistical analysis of costs
The costs were treated stochastically. P-values were reported for regression coefficients (type of test not reported but likely to be t-test for OLS) and R-squared for goodness of regression fit.
